GEHC

• William K. Grogan, formerly EVP and CFO of Xylem Inc., will become GE HealthCare's CFO on September 14, 2026.
• Grogan's compensation includes a $900,000 base salary, 100% target bonus, $3.3 million annual LTI target, and a $550,000 cash sign-on payment.
• He will receive a one-time sign-on equity award of $4,000,000 in RSUs vesting over two years, plus a 2026 annual LTI award of $3,300,000.
• Grogan succeeds Jay Saccaro, who previously stepped down for an expanded role outside the medical technology industry.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits

• Net income attributable to GE HealthCare was $561 million, up from $486 million in the prior-year quarter; diluted EPS was $1.24, up from $1.06.
• Adjusted EBIT was $750 million, up from $729 million; Adjusted EBIT margin was 14.2%, down 40 basis points year-over-year.
• Record organic orders growth of 11.1%, book-to-bill of 1.15 times, and backlog of $23.9 billion.
• Company reaffirmed full-year 2026 guidance: organic revenue growth of 3.0% to 4.0%, Adjusted EPS of $4.80 to $5.00, and free cash flow of approximately $1.6 billion.
• Patient Care Solutions segment revenue declined 13.3% organically; management is reviewing strategic options for the business.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• In Q2 2026, the company combined its Imaging and Advanced Visualization Solutions businesses into a new reportable segment, Advanced Imaging Solutions (AIS).
• The company now has three reportable segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS).
• The recast financials are provided for comparability and do not affect previously reported financial statements.
• The filing was made under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• On July 23, 2026, GE HealthCare named George Newcomb, Controller and Chief Accounting Officer, as interim CFO, effective August 14, 2026; he will continue in his current roles.
• No changes to Mr. Newcomb's compensation arrangements were made in connection with his appointment as interim CFO.
• GE HealthCare has commenced a search for a permanent CFO successor.
• The company also issued preliminary Q2 2026 results, including revenue growth of 5.7% and organic revenue growth of 3.5% year-over-year, and reaffirmed full-year 2026 guidance.

2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits

• At the May 7, 2026 annual meeting, shareholders elected eight directors to one-year terms, with each nominee receiving a majority of votes cast.
• Shareholders ratified the appointment of Deloitte & Touche LLP as independent auditor for fiscal year 2026, with 398,257,878 votes for.
• The Board appointed Rodney F. Hochman as independent lead director and Anne T. Madden as chairperson of the Nominating and Governance Committee, effective May 7, 2026.
• The report was filed under Item 5.07 to disclose voting results and Item 8.01 to disclose the board appointments.

5.07 Submission of Matters to a Vote of Security Holders · 8.01 Other Events

• Net income attributable to GE HealthCare was $389 million, down from $564 million in the prior year; diluted EPS was $0.85, down from $1.23.
• Adjusted EBIT was $691 million, down from $715 million; Adjusted EBIT margin was 13.5%, down 150 basis points year-over-year.
• Full-year 2026 guidance: organic revenue growth of 3.0% to 4.0% (unchanged), Adjusted EBIT margin of 15.4% to 15.7% (reduced from 15.8% to 16.1%), Adjusted EPS of $4.80 to $5.00 (reduced from $4.95 to $5.15), and Free cash flow of approximately $1.6 billion (reduced from approximately $1.7 billion).
• The company closed the acquisition of Intelerad for $2.3 billion and repurchased 1.4 million shares for $100 million in the quarter.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Kevin A. Lobo, Chair and CEO of Stryker Corporation, was appointed to the GE HealthCare Board of Directors effective March 13, 2026.
• He will receive compensation under the company's non-employee director program and will enter into an indemnification agreement.
• Directors Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting due to other commitments, with no disagreement with the company.
• A press release announcing the appointment was issued on March 17, 2026.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The new credit agreement, with JPMorgan Chase Bank as administrative agent, matures on February 25, 2027.
• The prior 364-day revolving credit agreement dated March 27, 2025, also for $0.5 billion, was terminated without penalty on February 26, 2026.
• Interest rates on borrowings are based on SOFR, EURIBOR, or SONIA plus an applicable margin determined by the Company's senior unsecured long-term debt ratings.
• The agreement includes customary covenants, including limits on liens, fundamental changes, leverage ratio, and subsidiary indebtedness, as well as customary events of default.

1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits